Bank of America Securities analyst Sachin Jain reiterated a Buy rating on Novo Nordisk (NVO – Research Report) today and set a price target of $174.00. The company’s shares closed yesterday at $140.99. Jain covers the Healthcare sector, focusing on stocks such as AstraZeneca, Novo Nordisk, and Arcus Biosciences. According to TipRanks, Jain has an average return of 9.9% and a 67.92% success rate on recommended stocks.  The word on The Street in general, suggests a Strong Buy analyst consensus rating for Novo Nordisk with a $158.48 average price target. See Insiders’ Hot Stocks on TipRanks >>  Based on Novo Nordisk’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $48.09 billion and a net profit of $13.59 billion. In comparison, last year the company earned a revenue of $38.33 billion and had a net profit of $10.89 billion
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.  Read More on NVO: Indices Commodities Currencies Stocks